Sign In
Buy CRVS
$11.60
-0.0900 (-0.770%)
At Close: Jun 03, 2026
Corvus Pharmaceuticals Provides Program Updates at R&D Symposium
11:30am, Tuesday, 10'th May 2022 GlobeNewswire Inc.
Highlights new interim data from CPI-818 Phase 1/1b study in patients with relapsed T cell lymphomas
Corvus Pharmaceuticals to Host R&D Symposium on May 10, 2022 in New York
11:30am, Tuesday, 26'th Apr 2022 GlobeNewswire Inc.
Company to host a webcast at 9:00am ET / 6:00am PT Company to host a webcast at 9:00am ET / 6:00am PT
Best Penny Stocks To Watch In April? 3 Insiders Are Buying Now
05:22pm, Monday, 04'th Apr 2022 PennyStocks
Penny stocks insiders are buying right now.
The post Best Penny Stocks To Watch In April? 3 Insiders Are Buying Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com
Best Penny Stocks To Watch In April? 3 Insiders Are Buying Now
01:22pm, Monday, 04'th Apr 2022
Penny stocks insiders are buying right now. The post Best Penny Stocks To Watch In April?
Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q4 2021 Results - Earnings Call Transcript
12:34am, Friday, 11'th Mar 2022 Seeking Alpha
Corvus Pharmaceuticals GAAP EPS of -$0.20 misses by $0.01
09:14pm, Thursday, 10'th Mar 2022 Seeking Alpha
Corvus Pharmaceuticals press release (CRVS): Q4 GAAP EPS of -$0.20 misses by $0.01.Q4 Cash and cash equivalents $69.45M
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
09:05pm, Thursday, 10'th Mar 2022 GlobeNewswire
Corvus to host conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT Corvus to host conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT
Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q4 2021 Results - Earnings Call Transcript
07:34pm, Thursday, 10'th Mar 2022
Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q4 2021 Results - Earnings Call Transcript
Corvus Pharmaceuticals Q4 2021 Earnings Preview
10:35pm, Wednesday, 09'th Mar 2022 Seeking Alpha
Corvus Pharmaceuticals (NASDAQ:CRVS) is scheduled to announce Q4 earnings results on Wednesday, March 9th, after market close.The consensus EPS Estimate is -$0.18 (-119.6% Y/Y) and…
Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022
09:30pm, Thursday, 03'rd Mar 2022 GlobeNewswire Inc.
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022
09:30pm, Thursday, 03'rd Mar 2022 GlobeNewswire
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022
04:30pm, Thursday, 03'rd Mar 2022
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
The Daily Biotech Pulse: Bausch Files For Eye Health Unit IPO, LumiraDx Antigen Test Can Detect Omicron, Molecular Partners Discloses Fund Stake
01:07pm, Friday, 14'th Jan 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Corvus Says Chinese Angel Pharma Starts Phase 1/2 Blood Cancer Study
Corvus Pharmaceuticals, Inc. (NAS
Corvus Pharma initiates Phase 1/1b trial of CPI-818 for T-cell lymphomas in China
11:19am, Friday, 14'th Jan 2022 Seeking Alpha
Corvus Pharmaceuticals'' (CRVS) partner Angel Pharmaceuticals has treated the first patient in its Phase 1/1b clinical trial of Corvus small molecule ITK inhibitor CPI-818 for
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Initiated Phase 1/1b Clinical Trial of ITK Inhibitor CPI-818 in China
11:30pm, Thursday, 13'th Jan 2022 GlobeNewswire Inc.
BURLINGAME, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that its partne
